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introduction: The oxidative stress associated with glucose variability might be respon-
sible for neuronal damage while autonomic neuropathy (AN) has a detrimental effect on 
metabolism. The aim of the study was to find relationship between AN and GV in type 1 
diabetic patients and to identify further factors that affect GV.
Patients and methods: Twenty type 1 diabetic patients were involved (age: 
39.5 ± 3.4 years, duration of diabetes: 17.5 ± 2.5 years; HbA1c: 8.1 ± 0.2%, mean ± SE). 
AN was assessed by the cardiovascular reflex tests. The interstitial glucose levels were 
determined following insertion of a subcutaneous electrode during the continuous 
glucose monitoring (CGM) method on six consecutive days. GV was characterized by 
calculation of four parameters.
results: SD of interstitial glucose values correlated positively with the overall AN score 
and the degree of the orthostatic reduction of systolic blood pressure (AN-score-SD 
ρ = 0.47, p < 0.05; orthostasis-SD: ρ = 0.51, p < 0.05). Mean absolute glucose (MAG) 
correlated with three parameters of AN (AN-score-MAG: ρ =  0.62, p <  0.01; 30/15 
ratio-MAG: ρ = −0.50, p < 0.05; orthostasis-MAG: ρ = 0.59, p < 0.01). The HbA1c 
also correlated with two parameters of GV (HbA1c-continuous overlapping net glycemic 
action: ρ = 0.56, p < 0.05; HbA1c-MAG: ρ = 0.45, p < 0.05). The frequency of hypogly-
cemia did not exhibit any correlation with measures of GV.
conclusion: Severity of glucose variability but not overall glucose load correlates with 
both parasympathetic and sympathetic dysfunctions in type 1 diabetes. Higher HbA1c 
is associated with more severe glucose variability. The observed correlation between 
increased glucose variability and the severity of AN necessitates the further exploration 
of this relationship.
Keywords: autonomic neuropathy, glucose variability, continuous glucose monitoring, type 1 diabetes, 
cardiovascular reflex tests
Abbreviations: AN, autonomic neuropathy; BMI, body mass index; CGM, continuous glucose monitoring; CGMS, continuous 
glucose monitoring system; CONGA, continuous overlapping net glycemic action; CRT, cardiovascular reflex test; GV, glucose 
variability; MAG, mean absolute glucose; MAGE, mean amplitude of glycemic excursions.
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inTrODUcTiOn
Large prospective trials provided clear evidence two decades ago 
that long-term hyperglycemia due to less intensive treatment 
is associated with micro- and macrovascular complications in 
patients with diabetes (1, 2). Later the detrimental role of recur-
rent hypoglycemic episodes and acute as well as chronic hypergly-
cemia was also proven in the development of severe disorders of 
several important organ systems (3, 4). Fasting and postprandial 
glucose as well as HbA1c are generally used in clinical studies 
and the everyday practice to express the glycemic control of 
diabetic patients. However, the value of all three parameters is 
limited as fluctuations of glucose are not characterized by them 
(5). Thus, the concept of glucose variability (GV) was introduced 
to describe the variations of glucose levels (6). The variability of 
blood or interstitial glucose as well as HbA1c reflects the level 
of deviations from the mean value of these parameters (7). 
Keeping the strict balance of carbohydrate metabolism is a real 
challenge in a diabetic patient as several factors may influence 
the actual glucose values such as age, cognitive impairment, 
or liver and kidney failure (8). Moreover, glycemic stability is 
influenced by antidiabetic therapy, diet, and body composition 
(9). Reduced beta-cell function is one of the most important 
risk factors of GV and an inverse relationship between residual 
C-peptide levels and glucose variability has been shown in type 1 
diabetic patients (10). Beta-cell dysfunction might be associated 
with glycemic instability in type 2 diabetic patients as well (11). 
In type 1 diabetic patients, hyperglycemia is primarily related 
to the loss of endogenous insulin secretion, while the impaired 
glucagon response to hypoglycemia explains the susceptibility to 
abnormally low glucose values (12). These observations suggest 
the hypothesis of a more pronounced GV in type 1 than in type 
2 diabetic subjects. However, most of the previous studies about 
the detrimental effects of GV were conducted on type 2 diabetic 
patients, and thus the possible differences in causes and conse-
quences of GV between type 1 and type 2 diabetic patients have 
not been clearly analyzed up to now. Exploration of the factors 
responsible for this metabolic situation in type 1 diabetes is an 
important aim of a clinical research. The potential role of auto-
nomic neuropathy (AN) in the development of higher GV should 
be studied as well. There is a considerable interplay between 
diabetic neuropathy and GV. On the one hand, the potential 
role of GV in the development of neuronal damage is discussed 
(13). On the other hand, manifestations of AN and peripheral 
neuropathy may lead to metabolic imbalance (14). In the present 
study, we aimed to assess a potential connection between GV and 
cardiovascular AN among patients with type 1 diabetes. We also 
investigated further possible pathogenetic factors of GV includ-
ing HbA1c, body mass index (BMI), gender, age, daily insulin 
dose, diabetes duration, and frequency of hypoglycemia.
MaTerials anD MeThODs
Patients
Twenty type 1 diabetic patients with diabetes were involved in the 
study (age: 39.5 ± 3.4 years, duration of diabetes: 17.5 ± 3.4 years; 
mean ± SE). They were non-obese (BMI: 22.3 ± 0.8 kg/m2) and 
their mean HbA1c was 8.1 ± 0.7%. All patients applied multiple 
daily injections of analog insulins, their mean daily insulin dose 
was 42.8 ±  2.9  U. Further anthropometric and clinical param-
eters of the patients can be found at Table S1 in Supplementary 
Material. Patients with atrial fibrillation, acute infection, thyroid 
disease, or chronic alcohol consumption were excluded from the 
study. The study was approved by the Regional Scientific and 
Research Ethical Committee of the Albert Szent-Györgyi Health 
Center at University of Szeged. All subjects have given written 
informed consent of the study.
assessment of an
Cardiovascular consequences of AN were detected to character-
ize the presence and severity of the neuronal dysfunction. The 
five standard cardiovascular reflex tests (CRT) were applied (15). 
These measurements provide a non-invasive, clinically relevant, 
reproducible, and standardized gold-standard determination of 
autonomic function (16). Three of these tests record the change 
of heart rate during specific maneuvers, while other two tests 
were designed to evaluate blood pressure changes (17). Most of 
the tests aiming to detect changes in heart rate are used primar-
ily (but not exclusively) for the assessment of parasympathetic 
innervation, while the blood pressure responses predominantly 
reflect the impairment of sympathetic functions. The heart 
rate changes were analyzed during deep breathing, in positions 
of lying and standing up (30/15 ratio), and during and after of 
Valsalva maneuver. Systolic blood pressure was determined 
in response from lying to standing up, and diastolic pressure 
change was measured during a sustained handgrip. The results of 
each CRT were correlated with the calculated parameters of GV. 
Finally each CRT was scored as 0 (normal), 1 (borderline), or 2 
(abnormal), and by this method an autonomic score (0–10) was 
calculated to express the overall severity of AN. Age-corrected 
normal reference values were applied based on the definition 
of Ewing and the recommendations of the Toronto Neuropathy 
Expert Group (17, 18). The tests were performed in postprandial 
state, after breakfast. In case of actual hypo- or hyperglycemia, the 
tests were not done.
Determination of gV
Glucose variability was calculated from the results of a con-
tinuous glucose monitoring (CGM) system (Ipro 2 with Enlite 
sensor, Medtronic Minimed Inc.). During this procedure, a tiny 
flexible electrode was placed under the skin. The electrode con-
tinuously measured the glucose levels of the interstitial fluid. 288 
glucose readings were detected per 24  h and the total period of 
continuous measurement was 6 days. The measured glucose values 
became available following the download of the detected data. SD, 
mean amplitude of glycemic excursions (MAGE), continuous over-
lapping net glycemic action (CONGA), and mean absolute glucose 
(MAG) of interstitial fluid were calculated to characterize GV (19).
analysis of Possible Pathogenetic Factors 
responsible for glucose Variability
To identify potential factors impacting on GV, HbA1c, BMI, age, 
diabetes duration, and daily insulin dose of patients were explored. 
Table 1 | Results of cardiovascular reflex tests and glucose variability 
parameters in type 1 diabetic patients.
autonomic neuropathy (an) test Type 1 diabetic  
patients (mean ± se)
Heart rate response to deep breathing 23.9 ± 2.6 (beats/min)
30/15 ratio 1.15 ± 0.07
Valsalva ratio 1.72 ± 0.13
Diastolic blood pressure response to handgrip 16.2 ± 2.7 (mm Hg)
Systolic blood pressure response to standing up 7.6 ± 1.4 (mm Hg)
AN score 2.1 ± 0.4
Patients without AN 10/20
Patients with early AN 5/20
Patients with severe AN 5/20
gV parameter
Continuous overlapping net glycemic action 8.09 ± 0.4 mmol/L
SD 3.49 ± 0.1 mmol/L
Mean amplitude of glycemic excursions 6.12 ± 0.2 mmol/L
Mean absolute glucose 2.25 ± 0.2 mmol/L
FigUre 1 | Correlations between SD of continuously measured interstitial glucose levels and cardiovascular reflex tests.
3
Nyiraty et al. AN and Glucose Variability
Frontiers in Endocrinology | www.frontiersin.org April 2018 | Volume 9 | Article 174
Different categories of hypoglycemia were also characterized. 
Measured hypoglycemia was defined when blood glucose was 
below 3.9  mmol/L detected by continuous glucose monitoring 
system (CGMS). Severe hypoglycemia was categorized if serious 
cognitive impairment requiring assistance from another person 
associated with blood glucose lower than 3.9 mmol/L occurred. 
Hypoglycemia unawareness was established if a measured hypo-
glycemia was not recognized by the patient.
Statistical analyses between different parameters of glucose 
variability and the patients’ characteristics were performed with 
the Spearman correlation test and multiple regression analysis. 
Statistical significance was defined by p <  0.05. The statistical 
analyses were performed using the SigmaStat 4.0 Systat Software 
package.
resUlTs
The mean values of the measured CRT and variability parameters 
in type 1 diabetic patients are listed in Table 1. The CRT mean 
values of the patient group reflected a moderate autonomic 
impairment, while all measured mean GV parameters of the 
patients were higher than the previously published reference 
values in healthy subjects (19). As a next step of the analysis, the 
patients were divided into two groups: patients with AN scores 
0–1 (n = 10) and patients with AN scores 2–10 (n = 10). The 
GV parameters were compared and no significant difference was 
proven between the groups with a tendency of higher GV param-
eters in the AN group (CONGA: 7.6 ± 0.55 vs 8.5 ± 0.56 mmol/L, 
p =  0.235; SD: 3.3 ±  0.15 vs 3.67 ±  0.18  mmol/L, p =  0.129, 
MAGE: 5.9  ±  0.4 vs 6.2  ±  0.16  mmol/L, p  =  0.678; MAG: 
2.16 ±  0.3 vs 2.33 ±  0.09 mmol/L, p =  0.06; patients without 
AN vs patients with AN, mean ± SE). The further analyses were 
done on the whole group (n =  20). The AN scores calculated 
from the CRT-s expressing the overall severity of cardiovascular 
AN correlated positively with the SD of continuously measured 
interstitial glucose levels (ρ =  0.47, p <  0.05; Figure  1) thus 
showing that higher glucose variability expressed with SD was 
associated with more severe cardiovascular AN in this group of 
type 1 diabetic patients. The statistical analysis revealed a further 
positive correlation between SD of the continuously measured 
glucose values and the systolic blood pressure response to 
standing (ρ = 0.51, p < 0.05; Figure 1). This observation reflects 
pronounced systolic fall of blood pressure due to sympathetic 
AN in the presence of GV characterized by higher SD. The 
relationship between GV and AN was further strengthened by 
the fact that MAG, a marker of GV correlated positively with the 
AN scores of the patients (ρ = 0.62, p < 0.01; Figure 2). Higher 
MAG values were associated with significantly lower results of 
the 30/15 ratio (heart rate response to standing). The negative 
correlation coefficient (ρ = −0.5, p <  0.05) reflects impaired 
cardiovascular autonomic function among patients with more 
severe GV (Figure  2). Similarly to SD, MAG also correlated 
positively with the degree of orthostatic systolic blood pressure 
fall supporting the association between GV and sympathetic 
dysfunction (ρ =  0.59, p <  0.01; Figure  2). When AN scores 
were also calculated after the exclusion of the handgrip tests, 
similarly, significant correlations were found between SD, MAG, 
and AN scores (SD-AN score: ρ =  0.62, p <  0.01, MAG-AN 
score: ρ = 0.51, p < 0.05). When the correlations were adjusted 
for HbA1c, age, and duration of diabetes at a multivariate 
analysis the relationship between SD and the systolic blood 
pressure response to standing remained significant (r =  0.49, 
p < 0.05). Higher HbA1c levels were associated with increased 
FigUre 2 | Correlations between the mean absolute glucose (MAG) of continuously measured interstitial glucose levels and cardiovascular reflex tests.
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GV as measured by CONGA (Figure  3) or MAG (Figure  3). 
This observation was proven by the positive statistical cor-
relation between HbA1c and CONGA (ρ = 0.56, p < 0.05) and 
MAG (ρ = 0.45, p < 0.05). No statistical correlations were found 
between age, duration of diabetes, daily insulin dose, or BMI 
of type 1 diabetic patients and various parameters of their GV. 
Finally, no associations were proven between glucose levels 
below 3.9 mmol/L and markers of GV or AN. Similarly, lack of 
correlation was observed between the number of severe hypo-
glycemic episodes or hypoglycemia unawareness and the GV 
parameters or the severity of AN (Table S2 in Supplementary 
Material).
FigUre 3 | Correlations between glucose variability parameters and HBA1c.
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DiscUssiOn
Our data show for the first time an association between car-
diovascular AN and higher GV in type 1 diabetic patients. The 
positive and negative significant statistical associations found 
in our study indicate increasing values of MAG and SD in the 
presence of more severe AN reflected by two CRT-s or the AN 
score. We have also found higher HbA1c in the presence of 
increased glucose variability, while patterns of hypoglycemia 
were not associated with AN or glucose variability. These 
results supplement the previously published observations in 
the literature.
Altered motor and sensory axonal functions were found in 
a study in patients with type 1 diabetes in the presence of high 
MAGE, an important marker of GV acquired from continuous 
interstitial glucose monitoring (20). In another study, type 1 
diabetic patients with painful neuropathy had a higher mean glu-
cose, a greater M-value, and more glycemic excursions compared 
with the painless group (21).
In DCCT, conducted on type 1 diabetic patients, GV calcu-
lated from the 7-point daily glucose profiles was not associated 
with the risk of development of retinopathy, nephropathy, or 
cardiovascular AN. The discrepant findings in DCCT with our 
study might be explained by different methods: the 7-point daily 
glucose profile is less sufficient to express GV than CGM applied 
in our study. Moreover, 30/15 ratio from the CRT-s was not 
performed in DCCT while we used it (22). Although GV often 
occurs in type 1 diabetic patients, the possible associations of 
this metabolic imbalance and neuropathy were more frequently 
analyzed in type 2 diabetic patients (23, 24). Glucose variability 
was identified as a risk factor of macrovascular complications 
as well as cardiovascular and malignant diseases but only in 
type 2 diabetic patients (25, 26). The connection between AN 
and hyper/or hypoglycemia is well documented. Autonomic 
nerve dysfunction is related to decreased hypoglycemia aware-
ness leading to late realization and non-efficient management 
of abnormally low glucose (27). Impaired counter-regulatory 
response of epinephrine, norepinephrine to hypoglycemia was 
found in AN explaining the clear association between the occur-
rence of severe hypoglycemia and advanced cardiovascular AN 
(28, 29). Finally, hypoglycemia-associated autonomic failure 
has been described (30). On the other hand, parasympathetic 
autonomic dysfunction has been shown to be associated with 
postprandial hyperglycemia among newly diagnosed type 2 
diabetic patients (31).
Slower gastric emptying mainly as a consequence of a para-
sympathetic involvement develops during the progression of dia-
betic neuronal damage (32). Gastroparesis in AN is considered as 
the underlying mechanism in patients with unexplained periods 
of hypoglycemia followed by hyperglycemia (33, 34). Abnormal 
gastrointestinal peptide release due to autonomic dysfunction 
(including pancreatic polypeptide, motilin) causes additional 
motility and secretory dysfunctions that result in abnormal 
carbohydrate absorption (35).
In our study, several parameters of GV acquired from 
continuous interstitial glucose measurement associated with 
results of CRT-s and HbA1c of type 1 diabetic patients with 
disease. Continuous interstitial glucose detection provides 
a more detailed glucose time series than the self-monitored 
capillary glucose sampling or the variability of HbA1c. This 
method ensures the calculation of at least 10 parameters that 
describe glycemic stability of diabetic patients (19). The mean 
values of GV parameters reflected serious glycemic instability 
in this group of patients with type 1 diabetes (Table 1). SD as 
the most widely applied parameter that shows a linear relation-
ship with mean glucose (9) correlated with the overall severity 
of cardiovascular AN and the systolic blood pressure response 
to standing. The SD of interstitial glucose values is higher in 
the presence of more severe AN and if blood pressure fall is 
more pronounced to standing. The orthostatic hypotension 
is a characteristic late symptom of advanced neuropathy and 
reflects a sympathetic dysfunction. This sympathetic impair-
ment is frequently associated with altered norepinephrine levels 
which might explain an abnormal counter-regulatory response 
to hypoglycemia. The other glucose variability marker, MAG, 
reflected more unstable glucose in our study, if the cumulative 
autonomic score was higher and two reflex tests were more 
abnormal. MAG is a summation of all absolute changes in glu-
cose, divided by the time elapsed during the measurements. One 
of the two reflex tests that correlated with MAG was a ratio of the 
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heart rate responses to standing reflecting mainly the parasym-
pathetic function, while the other, the orthostatic systolic blood 
pressure to standing supplied information on sympathetic func-
tion. Thus, parasympathetic and sympathetic functions are both 
altered if GV is enhanced. The statistical correlation between 
the measured glucose variability and cardiovascular autonomic 
functions support a final conclusion that there might be a causal 
relationship between glycemic instability and AN. The original 
correlations between AN score and GV indices were reproduced, 
when handgrip tests were excluded from the calculation of the 
AN scores of the patients. The low sensitivity and specificity of 
the handgrip test in the diagnosis of cardiovascular AN and its 
high dependency on hypertensive status and baseline diastolic 
BP were proven before (36). The similar significant correlations 
without handgrip tests support the hypothesis that handgrip 
has a low value in the measurement of AN and strengthens the 
observed correlations between autonomic function and GV. The 
relationship between AN and GV was clearly proven, although 
the mean severity of AN was moderate of the patients, while GV 
was severe (Table 1).
As an interesting finding, we detected two correlations 
between markers of GV and HbA1c. The general approach of 
the literature to the possible relationship of GV and HbA1c 
is that these parameters reflect different patterns of carbo-
hydrate metabolism: parameters of GV calculated from CGMS 
describe both hypo- and hyperglycemic episodes for a short-
term period, while HbA1c reflects mean blood glucose and 
primarily driven by the extent of hyperglycemia (37). One 
explanation of our finding is that the patients in this study 
might have spent more time in hyperglycemia than hypogly-
cemia if their variability markers were high. The hypoglycemic 
episodes were frequently followed by hyperglycemia and these 
intervals might have been added to the “purely” hyperglycemic 
episodes. The frequency or severity of the realized or measured 
hypoglycemic episodes in this study did not correlate with GV 
markers pointing also to the longer hyperglycemic intervals 
in our patients. The mean value of the HbA1c of the patients 
was over the target (8.1%) supporting the long-standing 
hyperglycemia. Analyzing the variability markers separately, 
MAG is relatively weakly associated with hypoglycemia and 
reflects more hyperglycemia. On the other hand, calculation 
of MAG includes a timing component and is not a purely 
amplitude describing parameter that might explain the paral-
lel change with HbA1c (38). The other parameter, CONGA is 
calculated from the difference between a current and earlier 
glucose measurements and expresses the SD of these differ-
ences reflecting definitely the timing of variability. These 
markers incorporating a time-dependent description of GV 
might have parallel kinetics with the change of HbA1c (39). 
The associations between HbA1c and GV as well as GV and 
AN allow conclusions that the higher HbA1c is responsible for 
AN and AN leads to GV but it also could be assumed that GV 
manifests in higher HbA1c that results AN.
We did not find significant correlation between number of 
any hypoglycemia, severe hypoglycemic episodes, or hypo-
glycemia unawareness and the severity of AN in our patients. 
In the EURODIAB IDDM Complications Study, only in case of 
a combined autonomic deficit in heart rate and blood pressure 
responses to standing was associated with a modest increase in 
the risk of severe hypoglycemia. Most of patients in our study had 
only a moderate AN. Moreover, in adults with type 1 diabetes in 
another study no relationship was found between hypoglycemia 
unawareness and autonomic dysfunction similarly with our 
observations (29, 40). A study on type 1 diabetic patients, however, 
had conflicting data with our findings in which autonomic func-
tion characterized with heart rate variability correlated with low 
blood glucose index and area under the curve for hypoglycemia 
of CGM measures (41). Thus, application of different methods 
from ours revealed correlation between autonomic function and 
hypoglycemia that necessitates further explorations about this 
relationship.
Several factors may impact GV, particularly longer duration 
of diabetes is associated with higher GV. However, when the 
correlations were adjusted for HbA1c, age, and diabetes dura-
tion at a multivariate analysis, the relationship between SD 
and the systolic blood pressure response to standing remained 
significant (r = 0.49, p < 0.05). Although the moderate sample 
size may explain why only the correlation between SD and 
orthostatic hypotension remained significant after adjustment 
for confounding variables, it is noteworthy to stress the con-
cept that in the presence of advanced AN a severe variability 
of glucose is observed in type 1 diabetic patients. Orthostatic 
hypotension is a characteristic sign of the late progressive 
stages of AN (17) and primarily refers to the impairment of the 
sympathetic autonomic function. Orthostatic blood pressure 
response was among the two tests associated with a high risk of 
severe hypoglycemia in the EURODIAB IDDM Complications 
Study (29). The increased risk of hypoglycemia leads to pro-
nounced GV in patients with impaired sympathetic function 
and is explained by the impaired counter-regulatory response 
to abnormally low glucose levels. The relatively low number 
of patients might be considered as a limitation of our study. 
Nevertheless, a similar or even smaller number of diabetic 
patients were recruited in other studies on the same field (27, 28, 
42, 43). It should be added that according to the protocol of 
our study, AN and CGMS assessments were performed only in 
those cases in which both were indicated as a part of a medical 
management. The lack of the assessment of the symptoms of AN 
are among the limitations although these would predict the pos-
sible presence of autonomic dysfunction. A further limitation is 
that not all but two of four GV parameters correlated with the 
AN tests. One of these parameters is the most frequently applied 
standard GV marker, the SD by which our data are comparable 
with further studies.
cOnclUsiOn
It can be concluded from our study that in type 1 diabetes, 
increased GV is in a close relationship with advanced AN and 
might be manifested in higher HbA1c. Due to our study design, it 
is not possible to differentiate whether glucose variability induces 
neuropathy or the glycemic instability is a consequence of neu-
ropathy. The nature of these relationships should be explored in 
further studies.
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